Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997;75(6):789-97.
doi: 10.1038/bjc.1997.142.

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA

Affiliations
Free PMC article

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA

O Nilsson et al. Br J Cancer. 1997.
Free PMC article

Abstract

Monoclonal antibodies were raised against prostate-specific antigen (PSA) by immunization with purified free PSA, i.e. not in complex with any protease inhibitor (F-PSA) and PSA in complex with alpha1-anti-chymotrypsin (PSA-ACT). Epitope mapping of PSA using the established monoclonal antibody revealed a complex pattern of independent and partly overlapping antigenic domains in the PSA molecule. Four independent antigenic domains and at least three partly overlapping domains were exposed both in F-PSA and in the PSA-ACT complex, while one antigenic domain was specific for F-PSA. The different domains contained both continuous and discontinuous epitopes. The combination of antibodies recognizing antigenic domains exposed both in F-PSA and PSA-ACT made it possible to develop several highly sensitive sandwich immunoassays for determination of total PSA, i.e. F-PSA + PSA-ACT, with the same molar response for F-PSA and PSA-ACT. Assays specific for F-PSA (cross-reactivity between F-PSA and PSA-ACT < 1%) were developed by the combination of antibodies recognizing epitopes exposed only in F-PSA and antibodies recognizing epitopes exposed both in F-PSA and PSA-ACT.

PubMed Disclaimer

References

    1. Invest Urol. 1979 Sep;17(2):159-63 - PubMed
    1. Cancer. 1992 Jul 1;70(1 Suppl):230-4 - PubMed
    1. Anal Biochem. 1984 Mar;137(2):335-43 - PubMed
    1. J Clin Invest. 1985 Nov;76(5):1899-903 - PubMed
    1. Proc Natl Acad Sci U S A. 1986 May;83(10):3166-70 - PubMed